Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamics Effect of Calcipotriol/Betamethasone Dipropionate in a New Administration Form in Subjects With Chronic Plaque Psoriasis.

NCT03898583 | Completed Phase 1

• 1 other identifier: LP0120-1391
• Study Type: interventional
• Target: 15
• Locations: 1 country
• Sites: 2

Brief Summary

To assess safety, tolerability and pharmacodynamics effect of treatment with microarray patches containing calcipotriol and betamethasone dipropionate.

Conditions

Psoriasis Vulgaris

Outcome Measures

Primary Outcomes (9)

• Overall number of treatment-emergent adverse events.

  First IMP application up to trial end (Day 50)

• Number of treatment-emergent application site reactions, by treatment

  First IMP application up to trial end (Day 50)

• Change from baseline to Day 22 (EoT) in haematology parameters.

  RBC, WBC, haemoglobin, haematocrit, platelets, white cell differentials; measured in SI units.

  From baseline up to EoT (Day 22)

• Change from baseline to Day 22 (EoT) in clinical chemistry parameters.

  Sodium, potassium, BUN, glucose, AST, ALT, gamma GT, AP, calcium, phosphate, albumin, total cholesterol, LDH, total protein, creatinine, total bilirubin; measured in SI units.

  From baseline to EoT (Day 22)

• Change from baseline to Day 22 (EoT) in urinalysis parameters, single parameters only to be listed if deviation from usual urine dip test.

  E.g., leukocytes, nitrite, pH, protein, glucose, ketones, urobilinogen, bilirubin, blood/haemoglobin, measured in SI units.

  From baseline to EoT (Day 22)

• Number of subjects with abnormal clinically significant findings of physical examination at Day 22 (EoT).

  Evaluation of physical examination (areas skin, heart, lung, abdomen, basic neurological status, general examination of eyes, ears, nose, throat), overall evaluation, assessed by investigator as 'normal', 'abnormal not clinically significant', 'abnormal clinically significant'.

  EoT (Day 22)

• Change from baseline to Day 22 (EoT) in systolic and diastolic blood pressure.

  Measured in mmHg.

  From baseline to EoT (Day 22)

• Change from baseline to Day 22 (EoT) in pulse.

  Measured in beats per minute.

  From baseline to EoT (Day 22)

• Frequency counts of overall tolerability assessment of skin reactions at Day 8, Day 15, Day 22, Day 36 and Day 50.

  (Assessment performed by an investigator using a 4-point score \['0 = very good', '1 = good', '2 = moderate', '3 = poor'\]).

  From baseline up to trial end (Day 50)

Secondary Outcomes (1)

• Change from baseline (pre-dose at Day 1) to Day 22 (EoT) in psoriatic infiltrate thickness.

  EoT (Day 22)

Study Arms (4)

Microarray patch A

EXPERIMENTAL

21 day treatment, once weekly, 3 applications in total, transdermal patch for cutaneous use

Drug: Microarray patch A

Microarray patch B

EXPERIMENTAL

21 day treatment, 3 times weekly, 9 applications in total, transdermal patch for cutaneous use

Drug: Microarray patch B

Vehicle

PLACEBO COMPARATOR

21 day treatment, once weekly, 3 applications in total, transdermal patch for cutaneous use, no active substance

Drug: Placebo

Daivobet

ACTIVE COMPARATOR

21 day treatment, paused on day 7, day 14 and day 21, Cutaneous use

Drug: Daivobet

Interventions

Microarray patch A DRUG

Microarray patch

Also known as: Calcipotriol, Betamethasone dipropionate

Microarray patch A

Microarray patch B DRUG

Microarray patch

Also known as: Calcipotriol, Betamethasone dipropionate

Microarray patch B

Placebo DRUG

Microarray patch vehicle

Vehicle

Daivobet DRUG

Daivobet Gel

Also known as: Calcipotriol, Betamethasone dipropionate

Daivobet

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects with psoriasis vulgaris in a chronic stable phase and mild to moderate plaque(s) covering a sufficient area to allocate 4 test fields on up to 3 comparable plaques.
• Men and women aged 18-70 years (inclusive).
• Sufficient target lesion(s) must be present on the trunk or extremities (excluding palms/soles); psoriatic lesions on the knees or elbows are not to be used as target lesions.
• Plaques to be treated should have a comparable thickness of the EPB of the inflammatory infiltrate of at least 200 μm.
• Plaques to be treated should have no more than a 2-fold difference in infiltrate thickness between the test fields.
• Physical examination of skin must be without abnormal, clinical significant findings other than psoriasis vulgaris unless the investigator considers an abnormality to be irrelevant to the trial outcome.

You may not qualify if:

• Other skin disease noted on physical examination that is considered by the investigator to be relevant to the outcome of the trial.
• Subjects with acute psoriasis guttata, psoriasis punctata, psoriasis erythrodermatica, pustular, exfoliative or inverse psoriasis.
• History of psoriasis that was unresponsive or poorly responsive to topical treatments.
• Topical antipsoriatics are not permitted on the same body area as plaques to be treated during the 4 weeks before first treatment and during the trial.
• Systemic treatment with antipsoriatics e.g. corticosteroids, cytostatics, retinoids, dimethylfumarate, apremilast in the 3 months before first treatment and during the trial.
• Systemic treatment with biological treatments: rituximab within 12 months, ustekinumab or secukinumab within 6 months before first treatment and during the trial.
• Systemic treatment with biological treatments within 3 months before first treatment and during the trial.
• Systemic treatment with any other biological treatments within the period of 5 half-lives of the biological before first treatment and during the trial.
• UV-therapy or extensive exposure to UV radiation or sunlight within 4 weeks before first treatment and during the trial.
• Treatment with concomitant medication that may affect and provoke or aggravate psoriasis, unless on a stable dose for 3 months before trial medication initiation.
• Any other topical medication on the plaques to be treated during the trial.
• Clinically significant abnormal vital signs (blood pressure, and pulse) at screening (V1).
• History/symptoms of a clinically significant illness before first treatment (past 5 years) and during the trial that in the investigator's opinion may place the subject at risk.
• History/symptoms of a clinically significant illness before first treatment (past 5 years) and during the trial that in the investigator's opinion may influence the trial outcome.
• Other clinically significant abnormal laboratory results.

Sponsors & Collaborators

• LEO Pharma: lead

Study Sites (2)

LEO Pharma investigational site

Berlin, 10783, Germany

Location

LEO Pharma investigational site

Hamburg, 20098, Germany

Location

MeSH Terms

Interventions

calcipotriene; betamethasone-17,21-dipropionate; betamethasone dipropionate, calcipotriol drug combination

Study Officials

• Medical Expert

  LEO Pharma

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: INVESTIGATOR
• Masking Details: The trial will be assessor-blinded with random assignment of the 2 microarray patches containing calcipotriol and betamethasone dipropionate, the vehicle (microarray patches without active substance) and the active comparator.
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Intra-individual comparison of all treatments

Study Record Dates

• First Submitted: March 29, 2019
• First Posted: April 2, 2019
• Study Start: April 15, 2019
• Primary Completion: October 29, 2019
• Study Completion: October 29, 2019
• Last Updated: February 24, 2025

Record last verified: 2020-09

Data Sharing

• IPD Sharing: Will not share

Locations

DE (2)